1
Tarran Jones
Mary M Bendig, Olivier J Leger, Jose Saldanha, S Tarran Jones, Ted A Yednock: Humanized antibodies against leukocyte adhesion molecule VLA-4. Athena Neurosciences, Townsend & Townsend & Crew, November 24, 1998: US05840299 (86 worldwide citation)

The invention provides humanized immunoglobulins that specifically bind to the VLA-4 ligand, and methods of treatment using the same. The methods are particularly useful for treatment of multiple sclerosis.


2
Dale B Schenk, Peter A Seubert, Carmen Vigo Pelfrey: Methods for the detection of soluble .beta.-amyloid peptide. Athena Neurosciences, Eli Lilly and Company, Townsend and Townsend and Crew, January 14, 1997: US05593846 (182 worldwide citation)

Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compoun ...


3
Peter A Seubert, Dale B Schenk, Lawrence C Fritz: Methods for monitoring cellular processing of .beta.-amyloid precursor protein. Athena Neurosciences, Eli Lilly and Company, Townsend and Townsend and Crew, August 15, 1995: US05441870 (130 worldwide citation)

Processing of .beta.-amyloid precursor protein (.beta.APP) is monitored by detecting the secretion of a soluble .beta.APP fragment resulting from cleavage of .beta.APP at the amino-terminus of .beta.-amyloid peptide. In vivo monitoring of secretion of the .beta.APP fragment may be monitored for diag ...


4
Michael G Schlossmacher, Dennis J Selkoe: Methods of screening for compounds which inhibit soluble .beta.-amyloid peptide production. Athena Neurosciences, Eli Lilly and Company, Townsend and Townsend and Crew, June 16, 1998: US05766846 (126 worldwide citation)

Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compoun ...


5
Lisa C McConlogue, Jun Zhao: Transgenic animals harboring APP allele having swedish mutation. Athena Neurosciences, Eli Lilly and Company, Townsend and Townsend and Crew, March 18, 1997: US05612486 (124 worldwide citation)

The invention provides transgenic non-human animals and transgenic non-human mammalian cells harboring a transgene encoding an APP polypeptide comprising the Swedish mutation.


6
Peter A Seubert, Dale B Schenk, Lawrence C Fritz: Antibodies and fragments thereof which bind the carboxyl-terminus of an amino-terminal fragment of .beta.APP. Athena Neurosciences, Eli Lilly and Company, John Storella, Jean Duvall, February 24, 1998: US05721130 (93 worldwide citation)

Processing of .beta.-amyloid precursor protein (.beta.APP) is monitored by detecting the secretion of a soluble .beta.APP fragment resulting from cleavage of .beta.APP at the amino-terminus of .beta.-amyloid peptide. In vivo monitoring of secretion of the .beta.APP fragment may be monitored for diag ...


7
Becker Gerald Wayne, Brems David Nettleship, Chaney Michael Owen, May Patrick Cornelious, Rydel Russel Eugene, Simmons Linda Karen, Tomaselli Kevin James: Pharmaceutical screens and antibodies.. Lilly Co Eli, Athena Neurosciences, August 31, 1994: EP0613007-A2 (89 worldwide citation)

This invention describes a series of assays useful in evaluating the efficacy of agents which inhibit the neurotoxic effects of beta -amyloid peptide. These assays employ beta -amyloid peptide which is in a predominantly beta -sheet conformation. This invention also encompasses antibodies having a s ...


8
Dale B Schenk, Michael G Schlossmacher, Dennis J Selkoe, Peter A Seubert, Carmen Vigo Pelfrey: Methods and compositions for the detection of soluble .beta.-amyloid peptide. Athena Neurosciences, Eli Lilly and Company, Brigham and Women s Hospital, Townsend and Townsend and Crew, November 17, 1998: US05837672 (81 worldwide citation)

Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compoun ...


9
Susanna M S Chrysler, Sukanto Sinha, Pamela S Keim, John P Anderson: .beta.-secretase. Athena Neurosciences, Townsend and Townsend and Crew, April 28, 1998: US05744346 (79 worldwide citation)

Compositions comprising a novel protease capable of cleaving .beta.-amyloid precursor protein on the amino-terminal side of the .beta.-amyloid peptide therein are provided. The protease is designated .beta.-secretase. The .beta.-secretase may be used in screening assays to identify .beta.-secretase ...


10
Peter A Seubert, Dale B Schenk, Lawrence C Fritz: Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein. Athena Neurosciences, Eli Lilly and Company, Jean M Duvall, John R Storella, February 25, 1997: US05605811 (74 worldwide citation)

The present invention provides methods for identifying beta amyloid production inhibitors, wherein cells are cultured under conditions which result in secretion of a soluble fragment of beta amyloid precursor protein. The amino acid sequence of the fragment extends from the amino terminus of beta AP ...